Biomea Fusion, a preclinical biotech developing small molecule therapies for genetically defined cancers, filed on Friday with the SEC to raise up to $100 million in an initial public offering.
Biomea is focused on the development of irreversible small molecule drugs to treat patients with genetically defined cancers. Its lead candidate, BMF-219, is an orally bioavailable, potent, and selective irreversible inhibitor of menin being developed for the treatment of liquid and solid tumors. The company is currently completing IND-enabling studies and expects to file an IND in the 2H21.
The Redwood City, CA-based company was founded in 2017 and plans to list on the Nasdaq under the symbol BMEA. Biomea Fusion filed confidentially on February 12, 2021. J.P. Morgan, Jefferies and Piper Sandler are the joint bookrunners on the deal. No pricing terms were disclosed.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.